Nabriva Therapeutics (NASDAQ:NBRV) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV) in a research report released on Monday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Nabriva Therapeutics Price Performance

The stock has a market cap of $45.46 million, a PE ratio of -0.07 and a beta of 1.53. The company has a debt-to-equity ratio of 0.12, a quick ratio of 0.52 and a current ratio of 0.85. Nabriva Therapeutics has a 12 month low of $1.22 and a 12 month high of $8.45.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration.